<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02947568</url>
  </required_header>
  <id_info>
    <org_study_id>Pecs_NAFLD_01</org_study_id>
    <nct_id>NCT02947568</nct_id>
  </id_info>
  <brief_title>Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease</brief_title>
  <acronym>NAFLDDMCKD</acronym>
  <official_title>Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teaching Hospital Markusovszky, Szombathely</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius Medical Care North America</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pecs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study investigates relationship between non-alcoholic fatty liver disease and its
      risk factors, such as genetic background and diseases, such as chronic kidney disease and
      diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is a multisystemic disease, also affecting
      extrahepatic organs (1,2,6). According to former data, not only the prevalence of chronic
      hepatic disease, chronic cardiovascular diseases, but also the prevalence of chronic kidney
      disease (CKD) is higher in NAFLD (4,7). A strong association has been shown between diabetes
      mellitus (DM) and NAFLD as well (3,5,10).

      Many genetical factors have been studied in the background of NAFLD. Many studies have proved
      the effect of patatin-like phospholipase domain-containing protein 3 gene (PNPLA3) (8,9).
      Effect of numerous genetical polymorphisms has been suggested behind oxidative stress
      responsible for NAFLD (8).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of NFS (NAFLD fibrosis score) and HSI (hepatic steatosis index) with underlying conditions</measure>
    <time_frame>2 years</time_frame>
    <description>The association of hepatic steatosis with chronic kidney disease, diabetes mellitus and the the persence of these two will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Association of genetical factors with NFS and HSI</measure>
    <time_frame>2 years</time_frame>
    <description>The association of hepatic steatosis with genetic factors will be assessed. In case of patatin-like phospholipase domain-containing protein 3 gene (PNPLA3) : rs738409, rs2281135, rs2294918 single nuclear polimorfism (SNP) will be examined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of hepatic steatosis with renal function</measure>
    <time_frame>2 years</time_frame>
    <description>The association of serum creatinine, eGFR, blood urea nitrogen, serum sodium, serum potassium, serum calcium with NFS and HSI will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of glucose metabolism parameters with hepaic steatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>Association of HbA1C, fructosamine, blood glucose, serum insulin, HOMAIR, serum uric acid with NFS and HSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of liver function and hepatic setatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>Association of serum bilirubine, serum GOT, serum GPT, serum GGT, serum ALP, serum LDH, INR, serum total protein, serum albumin with NFS and HSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of serum lipid profile and hepatic setatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>Association of serum total cholesterol, serum HDL-cholesterol, serum LDL-cholesterol, serum triglyceride, serum carnitine with NFS and HSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of iron metabolism parameters with hepatic setatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>association of serum iron, serum transferrine, serum transferrine saturation, serum ferritine with NFS and HSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship between blood count, sedimentation and inflammation with hepatic setatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>Association of blood count, erythrocyte sedimentation rate, CRP with NFS and HSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assotion of serum proteins with hepatic setatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>association of urinary total protein, urinary albumin, urinary total protein/creatinine ratio, urinary albumin/creatinine ratio with NFS and HSI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of pathological tyrosine isoforms with hepatic setatosis indices</measure>
    <time_frame>2 years</time_frame>
    <description>Association of serum meta-Tyr, serum ortho-Tyr, urinary meta-Tyr, urinary ortho-Tyr, urinary meta-Tyr/creatinine ratio, urinary ortho-Tyr/creatinine ratio with NFS and HSI</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <condition>Chronic Kidney Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>CKD</arm_group_label>
    <description>chronic kidney disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM</arm_group_label>
    <description>diabetes mellitus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD+DM</arm_group_label>
    <description>chronic kidney disease + diabetes mellitus</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>non-interventional study</intervention_name>
    <arm_group_label>CKD</arm_group_label>
    <arm_group_label>DM</arm_group_label>
    <arm_group_label>CKD+DM</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CKD without DM, or patients with DM without CKD, or patients with both CKD
        and DM, aged 18-90
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CKD (renal replacement therapy non excluded)

          -  DM

          -  CKD+DM

        Exclusion Criteria:

          -  alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gergő Attila Molnar, MD</last_name>
    <phone>+3672536050</phone>
    <email>gergo.molnar@aok.pte.hu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eszter Sélley, MD</last_name>
    <phone>+3672536050</phone>
    <email>eszter.selley@aok.pte.hu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Department of Medicine and Nephrological Center</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gergo A Molnar, MD, PhD</last_name>
      <phone>+3672536050</phone>
      <email>gergo.molnar@aok.pte.hu</email>
    </contact>
    <contact_backup>
      <last_name>Eszter Sélley, MD</last_name>
      <phone>+3672536050</phone>
      <email>eszter.selley@aok.pte.hu</email>
    </contact_backup>
    <investigator>
      <last_name>Béla Melegh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lilla Lakner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kulcsár Imre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bene Judit, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>István Wittmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
  </location_countries>
  <reference>
    <citation>1. Alp H, Karaarsian S, Selver EB,Atabek ME, Altin H, Baysal T. Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol 2013;29:1118-1125. 2. Byrne CD, Targher G: NAFLD: A multisystem disease. Review. Journal of Hepatology, 2015; 62:S47-S64. 3. Kasturiratne A, Weerasinghe S, Dassanayake AS, rajindrajith S, de Silva AP, Kato N, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013;60:384-391. 4. Li G, Shi W, Hug H, Chen Y, Liu L, Yin D. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med 2012;22:92-99. 5. Okamoto M, Takeda Y, Yoda Y, Kobayashi K, Fujino MA, Yamagata Z. The association of fatty liver and diabetes risk. J Epidemiol 2003;13:15-21. 6. Pacifico L, Di MM, De MA, Bezzi M, Osborn JF, Catalano C, et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 2014;59:461-470. 7. Targher G, Choncol MB, Byrne CD. CKD a nonalcoholic fatty liver disease. Am J Kidney Dis 2014;64:638-652. 8. Wood KL, Miller MH, Dillon JF. systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease BMJ Open Gastro 2015:2:e000019. doi10.1136/bmjgast-2014-000019 9. Zain SM, Mohamed R, Hyogo H, et al. A multi-ethnic study of a PNPLA3 variant and its association with disease severity in non-alcoholic fatty liver disease. Hum genet 2012;131:1145-1152. 10. Zuppini G, Fedeli U, Gennaro N, Saugo M, Targher G, Bonora E. Mortality from chronic liver diseases in diabetes. Am J Gastroenterol 2014;109:1020-1025.</citation>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pecs</investigator_affiliation>
    <investigator_full_name>Dr. Gergő Molnár</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Non-alcoholic Fatty Liver Disease</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Cross-sectional</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

